AstraZeneca’s first-in-class FDA approval for Truqap marred by surprise restriction – FiercePharma

by

  1. AstraZeneca’s first-in-class FDA approval for Truqap marred by surprise restriction FiercePharma
  2. AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment BioSpace
  3. TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer Business Wire
  4. FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations OncLive
  5. FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer Cancer Network
  6. View Full Coverage on Google News

Read original article here

Leave a Comment